News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS) Announces Acceptance of Avanafil Application in Europe


3/26/2012 10:23:49 AM

MOUNTAIN VIEW, Calif., March 26, 2012 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS) today announced that a Marketing Authorization Application (MAA) has been accepted by the European Medicines Agency (EMA) for the review of avanafil, its investigational drug for the treatment of erectile dysfunction (ED). The EMA submission follows the successful completion of an extensive phase 3 program for avanafil, which included over 1,350 patients.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES